PFIZER INC

PFE · Large cap · Calculated market cap · $162.6B · as of 2026-09-30

Company Stats

Market Cap: $162.6B; as of Sep 30, 2026
Shares Outstanding: 5.7B
Free Float: 100.0%

Income Statement

Revenue: $62.6B
Net Income: $7.8B
Non-cash Impairment: $4.9B
Revenue Growth, 3Y: -14.8%
FCF Margin, 3Y Avg: 12.7%
FCF Margin, Worst Year: 8.0%

Cash Flow

Free Cash Flow: $9.1B
FCF Yield: 5.6%
Owner FCF Yield: 5.1%

Balance Sheet

Cash & Equivalents: $1.1B

Returns & Capital

Dividends Paid: $9.8B
Dividend Yield: 6.0%
Dividend Payout, 3Y Avg: 226.9%
Buyback Yield, 3Y Avg: 0.0%
SBC, 3Y Avg: $733.7M

Cash Flow by Year

Year	Revenue	FCF	Margin
FY2025	$62.6B	$9.1B	14.5%
FY2024	$63.6B	$9.8B	15.5%
FY2023	$59.6B	$4.8B	8.0%
FY2022	$101.2B	$26.0B	25.7%
FY2021	$81.3B	$29.9B	36.7%

Annual filing data through FY ended December 31, 2025; shares and float as of November 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.

Company RSS

Earnings

Nov 3, 2026Pfizer Raises 2026 Outlook After Launched-Product Growth Aug 4, 2026Pfizer Swings to Loss on $4.3 Billion Impairment as Growth Slows

Other Coverage

September 28, 2026 QBook

Stronger demand supports expansion as pricing diverges September 23, 2026 Drug Pipeline

Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies September 23, 2026 Drug Pipeline

Lilly and Novo set the backdrop for a changing obesity pipeline September 23, 2026 Drug Pipeline

Pfizer’s Velsipity brings an oral option to ulcerative colitis September 23, 2026 Drug Pipeline

Pfizer’s oral GLP-1 program ended with danuglipron’s discontinuation August 14, 2026 Industry Earnings Roundup

Healthcare Earnings: Demand Surges, Costs Bite Back

The Tip Desk